Search

La simulation en santé est un outil pédagogique devenu indispensable à la formation des étudiants. Elle vise tant la formation initiale que la formation continue des professionnels de santé. Les articles les plus nombreux concernent le domaine infirmier, par ailleurs à l’origine de la simulation en santé. Les publications sont presque 2 fois moindres lorsqu’elles impliquent des médecins, 10 et 145 fois moindres, pour les pharmaciens et les préparateurs en pharmacie. En 2023, notre hôpital universitaire a élargi ses compétences en formation par le (re)développement d’un centre de simulation. Un appel à devenir formateur en simulation a été proposé à l’ensemble du personnel. Par ailleurs, les étudiants préparateurs en pharmacie devant faire des anamnèses médicamenteuses sont demandeurs d’une meilleure préparation en amont.

A prospective seroepidemiological survey was carried out in Luxembourg in 2000–2001 to determine the antibody status of the Luxembourg population against hepatitis A virus (HAV) and hepatitis B virus (HBV). One of the objectives of this survey was to assess the impact of the hepatitis B vaccination programme, which started in May 1996 and included a catch-up campaign for all adolescents aged 12–15 years. Venous blood from 2679 individuals was screened for the presence of antibodies to HAV antigen and antibodies to hepatitis B surface antigen (anti-HBs) using an enzyme immunoassay. Samples positive for anti-HBs were tested for antibody to hepatitis B core antigen (anti-HBc) using a chemiluminiscent microparticle immunoassay to distinguish between individuals with past exposure to vaccine or natural infection. The estimated age-standardized anti-HAV seroprevalence was 42·0% [95% confidence interval (CI) 39·8–44·1] in the population >4 years of age. Seroprevalence was age-dependent and highest in adult immigrants from Portugal and the former Yugoslavia. The age-standardized prevalence of anti-HBs and anti-HBc was estimated at 19·7% (95% CI 18·1–21·3) and 3·16% (95% CI 2·2–4·1) respectively. Anti-HBs seroprevalence exceeding 50% was found in the cohorts targeted by the routine hepatitis B vaccination programme, which started in 1996. Our study illustrates that most young people in Luxembourg are susceptible to HAV infection and that the hepatitis B vaccination programme is having a substantial impact on population immunity in children and teenagers.

A large serosurvey was carried out in Luxembourg in 2000–2001, to determine the population immunity against a number of vaccine-preventable infections including diphtheria and pertussis. Immunity to diphtheria and pertussis was assessed using an in-house neutralization assay and a commercial ELISA test respectively. Mean pertussis antibody activity decreased from 4 to 8 years of age, reflecting the effects of waning of vaccine-induced immunity. Mean pertussis antibody activity increased during adolescence due to infection in previously vaccinated individuals and levelled out after approximately 20 years of age. For adults >25 years age, a statistically significant 30% difference in mean antibody activity between men and women was observed. The proportion of seronegatives for diphtheria among children and adolescents aged <20 years was 2·5% reflecting the high vaccination coverage. The proportion seronegative for diphtheria tended to increase with age such that 42% of individuals aged >40 years were seronegative. Our study supports the recently introduced acellular pertussis vaccine booster at 6 years to reduce pertussis transmission in school-aged children and adolescents.

A serological prevalence survey was carried out in Luxembourg during 2000–2001 to determine the antibody status of the Luxembourg population against vaccine-preventable infections including varicella-zoster virus (VZV). ELISA tests performed on 2679 sera indicated that 96 (3·6%) of the study population were seronegative. Age-specific seroprevalence rose rapidly from approximately 70% at age 4 years to 90% at age 6 years to 95% at age 12 years. Significant heterogeneity of seroprevalence was observed between the six different primary schools. For age groups 0–5, 6–11 and 12+ years, we estimated an annual force of infection of 0·361 [95% confidence interval (CI) 0·31–0·415)], 0·204 (95% CI 0·12–0·29) and 0·05 (95% CI 0·024–0·082) respectively. Our results indicate that transmission of VZV is highest in children below the age of 6 years and that much lower levels of VZV transmission occur in secondary schools and throughout adulthood.

A serological prevalence survey was carried out in Luxembourg during 2000–2001 to determine the antibody status of the Luxembourg population against vaccine-preventable infections. Blood samples of children and adolescents were collected prospectively in randomly selected schools. Samples of adults were obtained through volunteer patients of the national health laboratory or of the mandatory pre-nuptial test. Measles, mumps and rubella (MMR) virus antibody concentrations were measured using commercial ELISA tests. Age-standardized prevalence of measles, mumps and rubella virus antibodies was found to be 96·58, 75·40 and 95·69% respectively. Significant age-dependence of serology was observed for all three infections, with study participants born after the introduction of the MMR vaccine experiencing a gradual decline of antibodies following vaccination in childhood. Older study participants who were more likely to have antibodies from natural infection had consistently higher titres than younger individuals. Present vaccination coverage with MMR appears to be sufficient to prevent large local outbreaks of measles and rubella, but probably not mumps.